In Reply: The IAS-USA Panel based its recommendations on the best current scientific evidence and will take new data into consideration when available. The panel did not consider ongoing current clinical trials whose outcomes are uncertain, and it does not in any way discourage the conduct of these trials.
The panel expects that patients enrolling in ongoing comparisons of the optimal time at which to initiate therapy will be informed of the evidence for early therapy, including risks and benefits, as part of the informed consent process. Although data on early initiation of therapy were derived mostly from large, well-designed observational studies, the panel's recommendation also drew on compelling randomized clinical trial data from the HIV Prevention Trials Network 052 study1 that support early treatment for individual benefit and prevention of transmission.
Thompson MA, Aberg JA, Volberding PA. Treatment of Human Immunodeficiency Virus in Adults—Reply. JAMA. 2012;308(15):1522–1523. doi:10.1001/jama.2012.12889
Customize your JAMA Network experience by selecting one or more topics from the list below.